Business Description
Allakos Inc
NAICS : 325412
SIC : 2834
ISIN : US01671P1003
Description
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.12 | |||||
| Equity-to-Asset | 0.69 | |||||
| Debt-to-Equity | 0.25 | |||||
| Debt-to-EBITDA | -0.22 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 11.4 | |||||
| 3-Year EPS without NRI Growth Rate | 11.6 | |||||
| 3-Year FCF Growth Rate | 16.5 | |||||
| 3-Year Book Growth Rate | -46.2 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 29.34 | |||||
| 9-Day RSI | 33.59 | |||||
| 14-Day RSI | 36.91 | |||||
| 6-1 Month Momentum % | -35.96 | |||||
| 12-1 Month Momentum % | -67.99 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.92 | |||||
| Quick Ratio | 4.92 | |||||
| Cash Ratio | 4.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.2 | |||||
| Shareholder Yield % | 7.87 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -75.14 | |||||
| ROA % | -58.65 | |||||
| ROIC % | -245.19 | |||||
| ROC (Joel Greenblatt) % | -299.17 | |||||
| ROCE % | -68.12 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.55 | |||||
| Price-to-Tangible-Book | 0.55 | |||||
| EV-to-EBIT | 0.18 | |||||
| EV-to-EBITDA | 0.19 | |||||
| EV-to-Forward-EBITDA | -1.39 | |||||
| EV-to-FCF | 0.32 | |||||
| Price-to-Net-Current-Asset-Value | 0.88 | |||||
| Price-to-Net-Cash | 0.97 | |||||
| Earnings Yield (Greenblatt) % | 541.54 | |||||
| FCF Yield % | -126.25 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers